NCT06144424CompletedPhase 2
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis (EASE)
Source: ClinicalTrials.gov · Last updated 24 Aug 2025
Brief summary (registry, in English)
This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitis
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- First submitted
- 10 Nov 2023
- Start date
- 25 Oct 2023
- Primary completion date
- 31 Jul 2024
- Lead sponsor
- Escient Pharmaceuticals, Inc
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT06144424
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 32
- From 25 Oct 2023 to the primary completion date, 31 Jul 2024
- 10 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other active skin diseases associated with chronic pruritus
- Clinically infected atopic dermatitis that requires antibiotic therapy
Other
- Use of specific treatments for atopic dermatitis
Who the study is looking for
- Clinically confirmed diagnosis of active atopic dermatitis for at least 1 year
- BSA of 3% to 20% and a vIGA-AD score of ≥3
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (10)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Innovaderm Research Inc. Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
| AllerVie Clinical Research Coordinator of this site? Confirm its status | Birmingham | United States | Unknown status |
| Optima Research Boardman Coordinator of this site? Confirm its status | Boardman | United States | Unknown status |
| J&S Studies, Inc. Coordinator of this site? Confirm its status | College Station | United States | Unknown status |
| RM Medical Research Inc Coordinator of this site? Confirm its status | Miami Lakes | United States | Unknown status |
| Indiana Clinical Trials Center Coordinator of this site? Confirm its status | Plainfield | United States | Unknown status |
| Lawrence J. Green, MD, LLC Coordinator of this site? Confirm its status | Rockville | United States | Unknown status |
| Jordan Valley Dermatology Center Coordinator of this site? Confirm its status | South Jordan | United States | Unknown status |
| Dermatology Specialists of Spokane Coordinator of this site? Confirm its status | Spokane | United States | Unknown status |
| Revival Research Institute, LLC Coordinator of this site? Confirm its status | Troy | United States | Unknown status |
Related publications
- EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study.Dermatol Ther (Heidelb) · 2026 · PMID 42629547
This page is information, not medical advice. Discuss any trial with your doctor.